RGX-314 is a potential new treatment for people with neovascular age-related macular degeneration (nAMD), also called wet AMD. This condition causes vision loss because new and leaky blood vessels form in the retina, the part of the eye that helps you see. Current treatments for wet AMD require regular eye injections every 4 to 12 weeks, which can be difficult for patients to keep up with. RGX-314 might offer a one-time gene therapy solution.

This study is in Phase 2, meaning it's testing how well RGX-314 works and how safe it is. Around 115 people will participate, divided into 6 groups. Some will receive RGX-314, while others will get the current standard treatment, called ranibizumab. Participants will be regularly checked to see if the therapy is working and if there are any side effects.

• Study involves various doses of RGX-314 across different groups.
• Participants must be between 50-89 years old and have responded to prior treatments.
• Excludes those with other eye conditions, recent surgeries, or specific medical histories.